Table 1.
Details of 2 cases who developed left ventricular dysfunction during Pmab treatment
| Case 1 | Case 2 | Non-LVD cases (n = 26) | |
|---|---|---|---|
| Age, years* | 72 | 49 | 63** (range: 32–91) |
| Organ metastases | Lung, liver, brain | Lung, liver, brain | Lung (15), liver (12), bone (6), others (6) |
| Body mass index | 16.9 | 26.2 | 22.5** (range: 17.3–27.1) |
| Comorbidity | HT | None | HT (4), DM (1), HL (2), other heart disease (2) |
| Total amount of epirubicin, mg/m2 | 300 | 600 | 153.8** (range: 0–450) |
| Previous Tmab administration | Yes | Yes | Yes 14/26 (54%) |
| No 12/26 (46%) | |||
| Total cycles of Tmab | 59 | 38 | 44** (range: 6–132) |
| Total cycles of Pmab | 6 | 13 | 26.4** (range: 6–87) |
HT, hypertension; DM, diabetes; HL, hyperlipidemia.
*
At the time when Pmab treatment started.
**
Mean values.